Search results
Showing results for
PGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs. PGN-EDO51 at 10 mg/kg was generally well tolerated; all treatment-related adverse events were mild. DM1 program on track to read out FREEDOM-DM1 15 mg/kg cohort in second half of 2025 and FREEDOM2-DM1 5 mg/kg cohort in Q1 2026.
“The BioEscalator is more than just an innovation centre, it’s a true community.”
Ana Carolina Borges, Alethio Therapeutics
“The advice and insights of experienced peers and the knowledge and network built through BioEscalator events have been hugely beneficial.”
Aneesh Aggarwal and Sooraj Achar, Akimbo Bio
“The BioEscalator brings together an exceptional mix of innovation, ambition and entrepreneurial spirit.”
Frederik Lassen, Omos Biosciences
“The facilities and support teams enabled us to focus on R&D rather than operational maintenance.”
Atherton Mutombwera, Hutano Diagnostics
“The support and flexibility from the BioEscalator team was invaluable throughout our growth journey.”
Hollie Coe, Base Genomics (now Exact Sciences Innovation)
“The BioEscalator team have been incredibly supportive over the course of our journey.”
Charlotte Casebourne, Theolytics
Accessibility Statement
The University of Oxford is committed to providing an accessible web presence that gives members of the public and members of the University community full access to University information, courses and activities offered publicly through the web. Our Equality Policy outlines our commitment to a culture which ‘maintains a working, learning and social environment in which the rights and dignity of all its staff and students are respected’.
